Brokers Issue Forecasts for Immunic FY2025 Earnings

Key Points

• Chardan Capital predicts Immunic will report a FY2025 earnings loss of ($0.65) per share, with a target stock price of $13.00, maintaining a "Buy" rating.
• Immunic's current full-year earnings consensus stands at ($0.94) per share, while other analysts have also set price targets around $10.00.
• Major institutional investors like Jane Street Group and Millennium Management have significantly increased their holdings in Immunic, indicating growing interest in the company.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for Immunic in a research note issued on Monday, September 29th. Chardan Capital analyst R. Li expects that the company will post earnings of ($0.65) per share for the year. Chardan Capital currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share.

Other equities analysts also recently issued reports about the company. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, September 26th. D. Boral Capital reiterated a "buy" rating and issued a $10.00 price target on shares of Immunic in a research note on Thursday, September 25th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $9.50.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $0.88 on Wednesday. The firm has a market cap of $86.97 million, a price-to-earnings ratio of -0.94 and a beta of 1.44. Immunic has a 1 year low of $0.56 and a 1 year high of $1.73. The stock's 50-day simple moving average is $0.89 and its 200-day simple moving average is $0.92.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02).

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC boosted its holdings in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. Millennium Management LLC boosted its holdings in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares in the last quarter. 683 Capital Management LLC boosted its holdings in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after purchasing an additional 200,000 shares in the last quarter. Aberdeen Group plc bought a new stake in Immunic in the first quarter worth $1,155,000. Finally, Focus Partners Wealth boosted its holdings in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock worth $2,816,000 after purchasing an additional 415,104 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.